Ardsley Advisory Partners LP Adma Biologics, Inc. Transaction History

Ardsley Advisory Partners LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$1.8 - $2.56 $169,380 - $240,896	-94,100 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$2.04 - $3.74 $6,120 - $11,220	-3,000 Reduced 3.09%	94,100 $225,000
Q2 2020 Aug 14, 2020	BUY	$2.42 - $3.29 $54,450 - $74,025	22,500 Added 30.16%	97,100 $285,000
Q4 2019 Feb 14, 2020	SELL	$3.89 - $5.15 $124,091 - $164,285	-31,900 Reduced 29.95%	74,600 $298,000
Q3 2019 Nov 14, 2019	BUY	$3.19 - $5.39 $12,415 - $20,977	3,892 Added 3.79%	106,500 $474,000
Q2 2019 Aug 13, 2019	BUY	$3.52 - $5.24 $145,404 - $216,453	41,308 Added 67.39%	102,608 $397,000
Q1 2019 May 15, 2019	BUY	$2.61 - $4.35 $29,493 - $49,154	11,300 Added 22.6%	61,300 $233,000
Q4 2018 Feb 14, 2019	SELL	$2.17 - $6.12 $108,500 - $306,000	-50,000 Reduced 50.0%	50,000 $120,000
Q3 2018 Nov 14, 2018	BUY	$4.39 - $6.85 $87,800 - $137,000	20,000 Added 25.0%	100,000 $621,000
Q2 2018 Aug 14, 2018	BUY	$4.39 - $5.44 $351,200 - $435,200	80,000 New	80,000 $361,000

339

182M

1.72M

846K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.05B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Ardsley Advisory Partners LP, based on Form 13F filings with the SEC.

Stay updated on Ardsley Advisory Partners LP with notifications on news.